Krystal Biotech Inc. reported first‑quarter 2026 results that surpassed consensus expectations, with revenue of $116.36 million and diluted earnings per share of $1.83. The company’s top‑line grew 32% year‑over‑year and 9% sequentially, while EPS rose 52.5% from $1.20 in Q1 2025 and 26% from the previous quarter, reflecting robust demand for its flagship product VYJUVEK.
Revenue growth was driven by strong domestic sales and a significant contribution from international markets, which generated $28.9 million in net revenue. The company’s global rollout of VYJUVEK, including launches in Europe and Japan, helped offset the higher insurance‑related costs that typically accompany a first quarter. The 32% year‑over‑year increase underscores the product’s expanding market penetration and the effectiveness of the company’s commercialization strategy.
EPS beat expectations by $0.38 per share, a 26% lift over the $1.45 consensus estimate. The company’s gross margin improved to 95% from 94% in the prior year, driven by manufacturing efficiencies and pricing power. Strong cost control and the high‑margin nature of VYJUVEK sales contributed to the earnings beat, while the company maintained disciplined operating expenses despite the higher insurance costs.
Management guided for Q2 2026 revenue of $126.45 million and EPS of $1.86, and for Q3 2026 revenue of $142.5 million and EPS of $2.21. The company reiterated its full‑year 2026 non‑GAAP R&D and SG&A expense guidance of $175 million to $195 million, signaling confidence in continued investment in its pipeline while maintaining a disciplined cost base. The guidance reflects optimism about the company’s commercial momentum, tempered by ongoing pricing negotiations in Germany and France that could affect near‑term revenue timing.
CEO Krish S. Krishnan highlighted the company’s “growth mode” across commercialization and the pipeline, noting that three platform‑designated candidates—KB407, KB111, and a fourth—strengthen the regulatory pathway and reduce future development risk. He emphasized that the company’s platform model, built on a redosable HSV‑1 vector, positions it for broader application beyond VYJUVEK.
Market reaction to the earnings was mixed. While the company’s strong financial performance and positive guidance attracted investor interest, concerns about the extended European pricing negotiations and recent insider selling led some investors to adopt a cautious stance. The mixed reaction reflects a balance between the company’s robust commercial traction and the uncertainties surrounding pricing and regulatory dynamics in key international markets.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.